We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+30.73%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$989M
AUM Growth
-$405M
(-29%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-47.17%
Top 10 Holdings %
Top 10 Hldgs %
77.09%
Holding
40
New
5
Increased
2
Reduced
13
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$34.6M |
| 2 |
DYAX
DYAX CORPORATION
DYAX
|
+$19.4M |
| 3 |
Akebia Therapeutics
AKBA
|
+$14.4M |
| 4 |
SCYNEXIS
SCYX
|
+$7.35M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$3.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$59.6M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$44.4M |
| 3 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$35M |
| 4 |
Arrowhead Research
ARWR
|
+$30.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$25.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
1
DELISTED
Achillion Pharmaceuticals
ACHN
| $170M | 17.21% |
22,486,007
-880,000
| -4% | -$3.51M |
|
2
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
| $119M | 11.99% |
5,250,000
| – | – |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $95.8M | 9.69% |
9,982,578
+2,546,108
| +34% | +$19.4M |
|
|
SGMO
4
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $91.6M | 9.26% |
6,000,000
| – | – |
|
5
Enanta Pharmaceuticals
ENTA
$362M
| $66.3M | 6.7% |
1,539,586
-1,492
| -0.1% | -$56.9K |
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $54.8M | 5.54% |
2,428,571
| – | – |
|
|
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
| $50.1M | 5.07% |
+200,500
| New | +$34.6M |
|
|
SGMO
8
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $42.6M | 4.31% |
2,791,305
-2,430,748
| -47% | -$35M |
|
9
BioCryst Pharmaceuticals
BCRX
$2.42B
| $40.8M | 4.12% |
3,198,529
-1,148,927
| -26% | -$11.2M |
|
|
VIRX
10
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $31.7M | 3.21% |
23,187
| – | – |
|
11
Novavax
NVAX
$1.21B
| $30.8M | 3.11% |
333,087
-163,826
| -33% | -$14.4M |
|
|
ACHN
12
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| $22.7M | 2.3% |
3,000,000
| – | – |
|
|
DVAX
13
DELISTED
Dynavax Technologies
DVAX
| $22.5M | 2.27% |
1,403,659
-384,736
| -22% | -$5.8M |
|
|
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $22.3M | 2.26% |
527,941
-1,209,915
| -70% | -$44.4M |
|
|
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
| $21.1M | 2.13% |
1,219,381
-219,667
| -15% | -$3.58M |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $19.4M | 1.96% |
38,836
+2,751
| +8% | +$882K |
|
17
TherapeuticsMD
TXMD
$23.8M
| $19M | 1.92% |
86,061
-110,708
| -56% | -$24.6M |
|
|
18
Akebia Therapeutics
AKBA
$338M
| $16.6M | 1.68% |
+597,363
| New | +$14.4M |
|
19
Xencor
XNCR
$1.45B
| $11.8M | 1.19% |
1,016,735
-1,708,265
| -63% | -$16.8M |
|
20
EyePoint Inc
EYPT
$999M
| $11.1M | 1.12% |
255,566
| – | – |
|
|
21
Arrowhead Research
ARWR
$12.1B
| $8.65M | 0.87% |
604,346
-2,337,570
| -79% | -$30.6M |
|
|
22
SCYNEXIS
SCYX
$37.4M
| $6.74M | 0.68% |
+10,500
| New | +$7.35M |
|
|
ALIM
23
DELISTED
Alimera Sciences
ALIM
| $3.99M | 0.4% |
44,444
| – | – |
|
|
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.75M | 0.38% |
490,697
-37,100
| -7% | -$296K |
|
|
IMMU
25
DELISTED
Immunomedics Inc
IMMU
| $3.65M | 0.37% |
+1,000,000
| New | +$3.67M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, RA Capital Management held 40 positions worth $989M, down 29% from $1.39B the previous quarter. Its ten largest holdings account for 77% of the portfolio.
RA Capital Management withdrew a net $467M in Q2 2014, closing 12 positions and reducing 13 holdings. Its most notable exit was Prothena Corp, an estimated $59.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 59% a quarter earlier.
Against the trend, RA Capital Management opened a new position in Aravive, Inc. Common Stock worth $50.1M.
- RA Capital Management's largest Q2 2014 buy was Aravive, Inc. Common Stock: 200,500 shares worth $50.1M.
- RA Capital Management added most to DYAX CORPORATION in Q2 2014, an estimated $19.4M increase.
- RA Capital Management's biggest Q2 2014 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $44.4M.
- RA Capital Management fully exited Prothena Corp in Q2 2014, selling an estimated $59.6M.
- RA Capital Management's ten largest holdings make up 77% of its $989M portfolio in Q2 2014.
- RA Capital Management opened 5 new positions and closed 12 in Q2 2014.
- RA Capital Management's portfolio value fell 29% quarter-over-quarter to $989M.
Based on RA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.